Table 1 Demographic and clinical characteristics of the included subjects
CA (n = 100) | HCM (n = 217) | P values | |
|---|---|---|---|
Age, years | 58.5 ± 10.7 | 50.7 ± 14.8 | < 0.001 |
Gender, females, n(%) | 41 (41%) | 101 (46.5%) | 0.318 |
BMI, kg/m2 | 22.0 ± 3.3 | 24.1 ± 3.5 | < 0.001 |
NYHA III-IV, n(%) | 64 (64%) | 23 (10.6%) | < 0.001 |
Hypertension, n(%) | 16 (16%) | 65 (30%) | 0.001 |
Diabetes, n(%) | 9 (9%) | 18 (8.3%) | 0.263 |
Dyslipidemia, n(%) | 7 (7%) | 12 (5.5%) | 0.823 |
Sub-types of HCM | |||
Asymmetrical/LOVOT | 37 | 168/124 | |
Concentric | 63 | 36 | |
Mid-ventricular | – | 2 | |
Apical | – | 11 | |
AL, n(%) | 93 (93%) | / | |
NT-proBNP, pg/ml | 8.5 ± 1.1 | 7.0 ± 1.0 | < 0.001 |
Troponin T, pg/ml | 4.6 ± 0.7 | 3.0 ± 0.9 | < 0.001 |
Medications | |||
Diuretics | 68 (68%) | 26 (12%) | |
β-blockers | 26 (26%) | 78 (35.9%) | |
ACEI/ARB | 12 (12%) | 31 (14.2%) | |
Ca2+ blockers | 5 (5%) | 33 (15.2%) | |
Statin | 8 (8%) | 22 (10.1%) | |
Cardiovascular magnetic resonance | |||
LV-ESV index, ml | 26.6 ± 9.5 | 23.9 ± 9.2 | 0.029 |
LV-EDV index, ml | 49.6 ± 11.4 | 59.8 ± 13.8 | < 0.001 |
LVEF, % | 46.6 ± 13.0 | 61.0 ± 7.9 | < 0.001 |
LV mass index, g/m2 | 43.3 ± 13.3 | 45.6 ± 17.5 | 0.25 |
MWT | 15.4 (14.5, 17.6) | 18.5 (16.2, 21.1) | < 0.001 |
Presence of main LGE pattern | |||
Patchy | 17 (24.3%) | 163 (75%) | |
Transmural | 25 (35.7%) | 54 (25%) | |
Subendocardial | 23 (32.8%) | ||
Diffuse | 5 (7.2%) | ||
LGE extent (g) | 55.9 (37.3, 81.3) | 10.2 (3.2, 25.2) | < 0.001 |
LGE extent (%) | 49.4 (37.4, 63.8) | 11.4 (4.5, 21.6) | < 0.001 |